These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23234585)

  • 1. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R; Germinario EA; Bonati M; Masi G; Zuddas A; Vella S; Chiarotti F; Panei P;
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
    Didoni A; Sequi M; Panei P; Bonati M;
    Eur J Clin Pharmacol; 2011 Oct; 67(10):1061-7. PubMed ID: 21538145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.
    Tobaiqy M; Stewart D; Helms PJ; Williams J; Crum J; Steer C; McLay J
    Drug Saf; 2011 Mar; 34(3):211-9. PubMed ID: 21332245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
    Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
    J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
    Panei P; Arcieri R
    Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
    Germinario EA; Arcieri R; Bonati M; Zuddas A; Masi G; Vella S; Chiarotti F; Panei P;
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):440-7. PubMed ID: 24024538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
    Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
    Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.